We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC APPROVES TEVA-BMS GENERIC PARAPLATIN DISTRIBUTION DEAL
FTC APPROVES TEVA-BMS GENERIC PARAPLATIN DISTRIBUTION DEAL
June 1, 2004
The FTC has given its blessing to a deal between Teva Pharmaceutical and Bristol-Myers Squibb (BMS) that lets Teva launch an authorized version of BMS’ cancer drug Paraplatin (carboplatin) nearly four months before other generic firms.